Holen Sie sich die Stockscreener-App
26.04
0.91%
0.2352
Schlusskurs vom Vortag:
$25.80
Offen:
$25.91
24-Stunden-Volumen:
278.95K
Relative Volume:
0.37
Marktkapitalisierung:
$1.93B
Einnahmen:
$105.97M
Nettoeinkommen (Verlust:
$-81.13M
KGV:
-24.13
EPS:
-1.0791
Netto-Cashflow:
$-35.43M
1W Leistung:
+7.54%
1M Leistung:
+8.12%
6M Leistung:
+56.04%
1J Leistung:
+137.77%
1-Tages-Spanne:
$25.71
$26.48
1-Wochen-Bereich:
$24.57
$26.72
52-Wochen-Spanne:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.02 | 1.92B | 105.97M | -81.13M | -35.43M | -1.0791 |
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.90 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.75 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME - MarketBeat
ZYME PE Ratio & Valuation, Is ZYME Overvalued - Intellectia AI
ZYME Technical Analysis & Stock Price Forecast - Intellectia AI
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks Inc. R (ZA8.DU) Q1 FY2025 earnings call transcript - Yahoo Finance
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Q3 2025 Zymeworks Inc Earnings Call Transcript - gurufocus.com
Trade Report: How sensitive is Zymeworks Inc to inflationMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
ZymeworksLeveraging Partnerships For Value - RTTNews
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Singapore
Trade Recap: Can Zymeworks Inc grow without dilution2026 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Zymeworks appoints Kristin Stafford as chief financial officer By Investing.com - Investing.com Australia
Zymeworks appoints Kristin Stafford as CFO - MSN
Zymeworks Inc. Announces Executive Changes, Effective from April 1, 2026 - marketscreener.com
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - wahanariau.com
Zymeworks Names Kristin Stafford as New Chief Financial Officer - tipranks.com
Zymeworks Appoints Kristin Stafford as Chief Financial Officer to Drive Strategic Growth and Value Creation - Minichart
Zymeworks appoints Kristin Stafford as chief financial officer - investing.com
Kristin Stafford named Zymeworks executive VP and CFO as Kenneth Galbraith steps down as interim CFO - TradingView
Kristin Stafford joins Zymeworks (Nasdaq: ZYME) as new Chief Financial Officer - Stock Titan
Royalty Pharma veteran Kristin Stafford takes CFO post at Zymeworks - Stock Titan
How Investors May Respond To Zymeworks (ZYME) Fast Track Nod For Ovarian Cancer ADC ZW191 - Yahoo Finance
FDA grants fast track status to Zymeworks’ ZW191 for ovarian cancer By Investing.com - za.investing.com
FDA grants fast track status to Zymeworks’ ZW191 for ovarian cancer - au.investing.com
Investment Report: Will Zymeworks Inc benefit from geopolitical trendsPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
Zymeworks Inc Receives U S Fda Fast Track Designation for Zw191 an Fra Targeting Antibody Drug Conjugate - marketscreener.com
Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191 - tipranks.com
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - ChartMill
Is New ZW191 and Pan-RAS ADC Data Acceptance Shifting The Investment Case For Zymeworks (ZYME)? - simplywall.st
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN
Assenagon Asset Management S.A. Sells 679,400 Shares of Zymeworks Inc. $ZYME - MarketBeat
A Look At Zymeworks (ZYME) Valuation As New AACR ADC Data Advances Its Cancer Pipeline - Sahm
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on November 18, 2025. - marketscreener.com
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach - TipRanks
Zymeworks Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Zymeworks Announces Participation in Upcoming Investor Conferences - Sahm
Aug Weekly: Does Zymeworks Inc stock have upside surprise potentialGap Up & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences - TipRanks
Published on: 2026-03-23 15:16:44 - baoquankhu1.vn
Zymeworks Inc. (ZYME) reports Q4 loss, lags revenue estimates - MSN
Zymeworks Inc stock faces biotech volatility amid pipeline updates and market shifts - AD HOC NEWS
Will Zymeworks Inc benefit from rising consumer demand2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting - GlobeNewswire
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - Koreabizwire
Zymeworks to present clinical data on cancer drug candidate at AACR - Investing.com Australia
Zymeworks to present clinical data on cancer drug candidate at AACR By Investing.com - Investing.com South Africa
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting - TipRanks
Zymeworks to Present Clinical and Preclinical Data on ADC - GlobeNewswire
New cancer drug conjugates aim at tough RAS tumors in Zymeworks data - Stock Titan
Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting - Bitget
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):